Severe hypertensive reactions to teniposide (VM-26) in infants with congenital leukemia

Two cases of infants with congenital leukemia who had severe, refractory hypertensive reactions to teniposide (VM-26) are described. Patients on a 5 mg/kg twice weekly schedule of teniposide had hypertensive reactions in which their systolic blood pressure was greater than 200 mm Hg after the second...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of pediatric hematology/oncology Vol. 9; no. 3; p. 239
Main Authors Shimizu, H, Frankel, L S, Culbert, S J
Format Journal Article
LanguageEnglish
Published United States 1987
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Female
Humans
Hypertension - chemically induced
Infant
Infant, Newborn
Leukemia, Lymphoid - congenital
Leukemia, Lymphoid - drug therapy
Leukemia, Myeloid - congenital
Leukemia, Myeloid - drug therapy
Podophyllotoxin - analogs & derivatives
Teniposide - adverse effects
Teniposide - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Two cases of infants with congenital leukemia who had severe, refractory hypertensive reactions to teniposide (VM-26) are described. Patients on a 5 mg/kg twice weekly schedule of teniposide had hypertensive reactions in which their systolic blood pressure was greater than 200 mm Hg after the second dose of teniposide. Hypertension combined with myelosuppression resulted in the patient's death in one case. Although the exact mechanism of this unusual toxicity of teniposide remains unknown, it might be an age-specific problem, considering the very young age of our patients. Meticulous monitoring of vital signs, including blood pressure, is mandatory in leukemic infants receiving teniposide.
ISSN:0192-8562